

Title (en)
COVALENT INHIBITORS OF KRAS G12C

Title (de)
KOVALENTE INHIBITOREN VON KRAS-G12C

Title (fr)
INHIBITEURS COVALENTS DE KRAS G12C

Publication
EP 3401314 A1 20181114 (EN)

Application
EP 17206812 A 20140314

Priority

- US 201361852123 P 20130315
- US 201361889480 P 20131010
- EP 14720375 A 20140314
- JO P20140098 A 20140313
- US 2014027504 W 20140314

Abstract (en)
Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.

IPC 8 full level
C07D 401/06 (2006.01); **A61K 31/496** (2006.01); **A61P 35/00** (2006.01); **C07D 417/06** (2006.01)

CPC (source: EP US)
A61P 35/00 (2017.12 - EP); **C07D 205/04** (2013.01 - EP US); **C07D 211/56** (2013.01 - EP US); **C07D 211/58** (2013.01 - EP US); **C07D 211/60** (2013.01 - EP US); **C07D 211/62** (2013.01 - EP US); **C07D 213/64** (2013.01 - EP US); **C07D 213/74** (2013.01 - EP US); **C07D 231/40** (2013.01 - EP US); **C07D 237/04** (2013.01 - EP US); **C07D 285/14** (2013.01 - EP US); **C07D 285/16** (2013.01 - EP US); **C07D 295/16** (2013.01 - EP US); **C07D 401/04** (2013.01 - EP US); **C07D 401/06** (2013.01 - EP); **C07D 401/12** (2013.01 - EP US); **C07D 403/04** (2013.01 - EP US); **C07D 403/06** (2013.01 - EP US); **C07D 403/12** (2013.01 - EP US); **C07D 405/06** (2013.01 - EP US); **C07D 417/06** (2013.01 - EP); **C07D 419/12** (2013.01 - EP US); **C07D 471/04** (2013.01 - EP US); **C07D 487/04** (2013.01 - EP US); **C07D 487/10** (2013.01 - EP US); **G01N 33/58** (2013.01 - US)

Citation (applicant)

- US 5323907 A 19940628 - KALVELAGE JOHN D [US]
- US 5052558 A 19911001 - CARTER DOUGLAS V [US]
- US 5033252 A 19910723 - CARTER DOUGLAS V [US]
- WO 9633172 A1 19961024 - PFIZER [US], et al
- WO 9627583 A1 19960912 - PFIZER [US], et al
- EP 97304971 A 19970708
- EP 99308617 A 19991029
- WO 9807697 A1 19980226 - PFIZER [US], et al
- WO 9803516 A1 19980129 - PFIZER [US], et al
- WO 9834918 A1 19980813 - PFIZER [US], et al
- WO 9834915 A1 19980813 - PFIZER [US], et al
- WO 9833768 A1 19980806 - PFIZER PROD INC [US], et al
- WO 9830566 A1 19980716 - PFIZER [US], et al
- EP 0606046 A1 19940713 - CIBA GEIGY AG [CH]
- EP 0931788 A2 19990728 - PFIZER LTD [GB], et al
- WO 9005719 A1 19900531 - BRITISH BIO TECHNOLOGY [GB]
- WO 9952910 A1 19991021 - PFIZER PROD INC [US], et al
- WO 9952889 A1 19991021 - PFIZER PROD INC [US], et al
- WO 9929667 A1 19990617 - PFIZER LTD [GB], et al
- IB 9801113 W 19980721
- EP 99302232 A 19990323
- GB 9912961 A 19990603
- US 14846499 P 19990812
- US 5863949 A 19990126 - ROBINSON RALPH P [US], et al
- US 5861510 A 19990119 - PISCOPIO ANTHONY [US], et al
- EP 0780386 A1 19970625 - HOFFMANN LA ROCHE [CH], et al
- BUNDGARD, H.: "Design of Prodrugs", 1985, ELSEVIER, pages: 7 - 9,21-24
- HIGUCHI, T. ET AL.: "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14
- "Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
- GREEN, T.W.; P.G.M. WUTZ: "Protective Groups in Organic Synthesis", 1999, WILEY
- "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", December 2000, WILEY
- "Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING COMPANY
- HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO.
- "Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
- "Pharmaceutical Dosage Forms and Drug Delivery Systems", 1999, LIPPINCOTT WILLIAMS & WILKINS
- GOODMAN; GILMAN'S: "The Pharmacological Basis of Therapeutics"

Citation (search report)

- [A] EP 0655442 B1 20010523 - FUJISAWA PHARMACEUTICAL CO [JP]
- [A] US 4656181 A 19870407 - SUNKEL CARLOS E [ES], et al
- [A] US 2004106634 A1 20040603 - SATOH YOSHITAKA [US], et al
- [A] WO 9835951 A2 19980820 - FUJISAWA PHARMACEUTICAL CO [JP], et al
- [A] WO 2006097261 A1 20060921 - HOFFMANN LA ROCHE [CH], et al
- [A] EP 1348434 A1 20031001 - FUJISAWA DEUTSCHLAND GMBH [DE]
- [A] US 2005119266 A1 20050602 - SHI YAN [US], et al

- [A] WO 2004033427 A1 20040422 - ASTRAZENECA AB [SE], et al
- [A] WO 0204420 A1 20020117 - NOVARTIS AG [CH], et al
- [A] WO 02080928 A1 20021017 - MERCK & CO INC [US], et al
- [A] EP 2133334 A1 20091216 - DAC SRL [IT]
- [A] WO 2007047146 A2 20070426 - INTERMUNE INC [US], et al
- [A] WO 9730992 A1 19970828 - BRISTOL MYERS SQUIBB CO [US]
- [A] SUNDBERG R J ET AL: "THE O-STYRYLNITRENE ROUTE TO 2-SUBSTITUTED INDOLES. PYROLYSIS OF O-AZIDOSTYRENES", JOURNAL OF ORGANIC CHEMISTRY, WILLIAMS & WILKINS, US, vol. 37, no. 5, 1 January 1972 (1972-01-01), pages 719 - 724, XP002474920, ISSN: 0022-3263, DOI: 10.1021/JO00970A010

Cited by

US11299491B2; US11053226B2; US11285156B2; US11045484B2; US11096939B2; US11306087B2; US11993597B2; US10988485B2; US11285135B2; US11905281B2; WO2020106647A3; US11236091B2; US11827635B2; US11090304B2; US11426404B2; US11439645B2; US11766436B2; US11918584B2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

WO 2014152588 A1 20140925; AU 2014239542 A1 20151001; AU 2018214014 A1 20180823; AU 2018214014 B2 20200820; AU 2018214014 C1 20210429; CA 2904393 A1 20140925; CN 105189456 A 20151223; CN 105189456 B 20171219; EP 2970121 A1 20160120; EP 2970121 B1 20171213; EP 3401314 A1 20181114; EP 3401314 B1 20231108; HK 1215029 A1 20160812; JP 2016519072 A 20160630; JP 2019085414 A 20190606; JP 6473133 B2 20190220; JP 6849711 B2 20210324; MX 2015012054 A 20160406; MX 364438 B 20190426; TW 201524952 A 20150701

DOCDB simple family (application)

US 2014027504 W 20140314; AU 2014239542 A 20140314; AU 2018214014 A 20180807; CA 2904393 A 20140314; CN 201480025340 A 20140314; EP 14720375 A 20140314; EP 17206812 A 20140314; HK 16103063 A 20160316; JP 2016502462 A 20140314; JP 2019010309 A 20190124; MX 2015012054 A 20140314; TW 103109459 A 20140314